NSE: BIOCON · 23 October 2026
- Biocon Limited (BIOCON) shares declined 2.06% during the trading session on October 23, 2026, settling at ₹323.50 after moving between an intraday high of ₹330.90 and a low of ₹318.40.
- Biocon announced a global patent settlement and license agreement with Genentech regarding its Pebrilzo biosimilar referencing Perjeta. The agreement resolves pending disputes across the U.S., Canada, and other regions, setting licensed launch dates in Q1 of CY 2027 for the EU and UK, Q3 of CY 2028 for the U.S., and between CY 2026 and 2028 for other international markets.
- Trading volume was 1.35 times the 20-day average daily volume.
Why is Biocon Limited. share price falling on 23 October 2026?
Biocon Limited (BIOCON) shares declined 2.06% during the trading session on October 23, 2026, settling at ₹323.50 after moving between an intraday high of ₹330.90 and a low of ₹318.40.
The broader market and sectoral sentiment remained under pressure during the session. The benchmark Nifty declined 0.39%, while the Nifty Pharma sector index fell 1.04%. Biocon's downward move occurred alongside this broader sectoral weakness, adding to an extended pullback that reflects a 8.10% decline over the past 5 trading days and an 18.10% drop over the past 20 trading days.
Company disclosures from earlier in October provided broader context, including a global patent settlement with Genentech securing early launch dates for Pebrilzo and a GST order-in-original demand from Andhra Pradesh tax authorities involving financial year 2022-23. However, given that these operational and regulatory filings were made weeks prior, today's price action appears aligned with broader pharmaceutical sector weakness and technical consolidation following recent downward momentum.
34.71 lakh shares traded by 23 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 25.72 lakh shares (1.35 times). The five-day average daily volume was 22.84 lakh shares. Separately, the NSE report for 23 October 2026 showed 18.25 lakh shares delivered, representing 52.58% of that day’s traded volume. The same report recorded 51,014 trades.
The stock moved lower in tandem with weakness across pharmaceutical sector benchmarks and ongoing downward momentum over multiple trading days, with no specific catalyst reported on the day of the move.
Latest Company Developments
Biocon announced a global patent settlement and license agreement with Genentech regarding its Pebrilzo biosimilar referencing Perjeta. The agreement resolves pending disputes across the U.S., Canada, and other regions, setting licensed launch dates in Q1 of CY 2027 for the EU and UK, Q3 of CY 2028 for the U.S., and between CY 2026 and 2028 for other international markets.
It clears regulatory and legal overhangs, providing clear commercialization visibility and entry timelines for a key oncology biosimilar across major global markets.
The company disclosed the receipt of an Order-in-Original from the Office of the Assistant Commissioner (ST) in Andhra Pradesh for financial year 2022-23. The order confirms a tax demand of ₹1,85,28,762, interest of ₹1,17,59,033, and a penalty of ₹18,52,476 relating to SEZ documentation, input tax reversals, and input service distribution credits.
While management noted no material financial impact, it highlights ongoing tax compliance matters that the company intends to address through rectification applications or appeals.
a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Communication regarding remittance of final dividend for the FY 2025-26.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 22.08% on 30 September 2026. This compares with 15.47% on 30 June 2026, a change of +6.61 percentage points.
The filing reported 40 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and preliminary preparation for the scheduled Q1 CY 2027 European launch of Pebrilzo
- Developments regarding the tax rectification application or appeal filed against the Andhra Pradesh GST order
- Volume trends and delivery percentages relative to the 20-day average volume benchmark
- Sectoral performance of the Nifty Pharma index to gauge near-term sentiment alignment
Other Dated Coverage
- Biocon in Focus After Global Patent Settlement for Pebrilzo | 15 October 2026 — 15 October 2026
- Biocon Limited. Share Price Today: Why BIOCON Is Rising 0.82% | 14 October 2026 — 14 October 2026
- Biocon Limited. Share Price Today: Why BIOCON Is Falling 2.47% | 7 October 2026 — 7 October 2026
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
Biocon announced a global patent settlement and license agreement with Genentech regarding its Pebrilzo biosimilar referencing Perjeta. The agreement resolves pending disputes across the U.S., Canada, and other regions, setting licensed launch dates in Q1 of CY 2027 for the EU and UK, Q3 of CY 2028 for the U.S., and between CY 2026 and 2028 for other international markets.
How strong was Biocon Limited.’s trading volume?
34.71 lakh shares traded, 1.35 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.